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RESEARCH LETTER
Peak cough ﬂow measurement
with  a pneumotacograph and a
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Figure  1  Coughs  by  patient:  Bland--Altman  plot  of  the
agreement  in  measuring  peak  cough  ﬂow  (L/min)  between
the pneumotochograph  measurement  system  and  the  peak
ﬂow meter.  The  difference  between  two  measurements
(pneumotachograph-peak  ﬂow  meter)  is  plotted  against  the
mean of  two  measurements.  Solid  line  indicates  the  line  of
equality  (no  difference  between  measurements).  Three  dashed
lines indicate  the  difference  between  measurements  (bias)  and
the upper  and  lower  95%  limits  of  agreement  (bias  ±  1.96SD).
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To  the  Editor:
Patients  with  neuromuscular  diseases  (NMD)  have  weak
respiratory  muscles  that  may  affect  their  ability  to  cough
and  the  effectiveness  of  mucus  clearance.1 Peak  cough
ﬂow  (PCF)  values  can  be  measured,  through  a  peak  ﬂow
meter  (PCFm)  or  through  a  pneumotachograph  (PCFp),
and  have  been  proposed  to  assess  cough  capacity,1 esti-
mate  glottic  function2,3 and  predict  the  risk  for  respiratory
complications  in  patients  with  neuromuscular  diseases.4
Flows  of  160  L/min  have  been  reported  to  be  the  mini-
mum  needed  to  cough  effectively  and  are  associated  with
successful  extubation  or  tracheostomy  tube  decannulation
rates.5 Low  values  of  PCF  are  used  as  indication  crite-
ria  for  Mechanical  Insufﬂation--Exsufﬂation  (MI-E).  It  has
been  shown  that  MI-E  can  be  useful  when  PCFs  are  below
270  L/min  in  patients  with  Duchenne  muscular  dystrophy
with  a  high  risk  of  pulmonary  complications  during  respi-
ratory  tract  infections.6,7
Despite  the  absence  of  precise  threshold  values,  the  mea-
surements  of  PCF  are  very  important  in  clinical  practice.  As
NMD  patients  usually  perform  pulmonary  function  evalua-
tion  in  a  laboratory  on  a  regular  basis,  it  seems  useful  to  take
advantage  of  the  very  sensitive  ﬂow  sensor  of  the  spirometer
(pneumotachograph).  Therefore,  the  authors  aimed  to  com-
pare  non-assisted  PCF  values  obtained  with  both  methods
(PCFp  and  PCFm)  in  a  group  of  patients  with  NMD  followed
and  accessed  in  an  outpatient  clinic  between  2009  and  2013.
Measurements  through  PCFp  and  PCFm  were  performed
in  the  same  order  on  the  same  day,  after  a  resting
period  of  three  to  ﬁve  minutes  without  fatigue  between
them.  All  patients  that  presented  swallowing  and  speech
impairment  and  therefore  severe  bulbar  muscle  dysfunction
were  excluded.  The  cough  evaluation  was  performed  in  25
patients  with  several  types  of  muscular  dystrophies  (MD),  21Please  cite  this  article  in  press  as:  Rodrigues  PR,  et  al.
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patients  with  Amyotrophic  lateral  sclerosis  (ALS),  6  patients
with  spinal  muscular  atrophy  (SMA)  type  II,  3  patients  with
metabolic  myopathies  and  one  patient  with  multiple  sclero-
sis.
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BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)he bias  (95%  limits  of  agreement)  was  87.11  L/min  (−82.29  to
56.50 L/min).
Mean  values  of  non-assisted  PCFm  and  PCFp
ere  160.91  ±  94.84  L/min  and  248.49  ±  113.63  L/min
p  <  0.0001),  respectively.  Bland--Altman  analysis  was  used
o  compare  peak  ﬂow  measurements  obtained  from  the
neumotachograph  and  a  peak  ﬂow  meter.  Fixed  bias  was
nalyzed  by  describing  mean  bias  across  the  range  and
alculating  95%  limits  of  agreement  from  the  standard
eviation  (SD)  of  differences.  Bland--Altman  analysis  of  our
euromuscular  patients’  PCF  measurements  indicated  that
he  PCFm  measurements  were  markedly  lower  than  the
neumotachograph  system  (mean  95%  limits  of  agreement)
ias  87.11  L/min  (−82.29  to  256.50  L/min)  (Fig.  1).
The  results  obtained  in  this  study  were  different  from  the Peak  cough  ﬂow  measurement  with  a  pneumotaco-
h  neuromuscular  diseases.  Rev  Port  Pneumol.  2016.
ndings  by  Sancho  et  al.2 which  compared  both  measures
n  a  population  of  healthy  subjects  and  patients  with  neu-
omuscular  disease.  The  mean  of  the  differences  between
Elsevier Espan˜a, S.L.U. This is an open access article under the CC
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he  values  obtained  using  both  instruments  ±  limits  of  agree-
ent  (+2  SD)  was  0.20  ±  109.78  l/min  (not  signiﬁcant).
hen  the  agreement  was  tested  over  three  ranges  of  ﬂows
<270  l/min,  270--480  l/min,  and  >480  l/min)  no  statistically
igniﬁcant  differences  were  obtained  for  the  population  as
 whole  in  any  range;  although,  in  the  lower  ﬂow  range,  14
atients  had  PCFm  signiﬁcantly  greater  than  PCFp.
Kulnik  et  al.,8 performed  a  similar  comparison  of
on-assisted  PCF  measurements  in  healthy  subjects  and
land--Altman  analyses  of  volunteers’  PCF  measurements
ndicated  that  all  portable  devices  under  test  returned  lower
eadings  than  the  pneumotachograph  system,  regardless
f  whether  measurements  were  taken  when  connected  in
eries  or  in  isolation.  The  differences  in  measured  peak  ﬂow
etween  the  pneumotachograph  and  alternative  devices
ere  smaller  when  the  instruments  were  connected  in
eries;  and  larger  when  the  instruments  were  used  in  iso-
ation.
We  conclude  that  it  is  relevant  to  obtain  a  correct  and
ccurate  measurement  of  PCFs,  since  these  values  of  cough
fﬁcacy  have  important  clinical  implications  on  the  risk
f  respiratory  infections  and  on  the  criteria  for  manual
nd  mechanical  assisted  coughing  techniques.9,10 Our  results
uggest  that  the  PCF  measured  through  a  pneumotachograph
s  more  sensitive  and  accurate  in  patients  with  predicted
ough  impairment.  Although  the  values  through  PCFm  can
e  useful,  until  further  studies,  it  seems  reasonable  to  use
he  measurement  of  PCF-p  in  the  cough  evaluation  of  NMD
atients.
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